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Background: Perioperative management of antiplatelet agents in subjects who have received percutaneous coronary intervention (PCI) remains 
problematic. Continuation of these agents may heighten bleeding risk, while premature discontinuation may lead to fatal cardiovascular events. 
Anecdotally, we have observed the frequent practice of perioperative antiplatelet discontinuation and sought to retrospectively analyze the 
implications of this practice at our institution.
Methods: Subjects receiving noncardiac surgery within one year following PCI were identified from a database. These subjects were stratified 
according to the type of PCI performed (angioplasty or bare metal stent [BMS] versus drug-eluting stent [DES]), and whether clopidogrel was 
discontinued perioperatively. Information on demographics, comorbidities, and adverse cardiovascular events was collected. Adverse cardiovascular 
events were defined as myocardial infarction [MI], death due to cardiovascular causes, or unplanned revascularization within 30 days of the 
procedure. Continuous and categorical variables were analyzed using t-test and chi-square analysis, respectively.
Results: Of 1552 interventions total, 56 patients fulfilled inclusion criteria, with 29 (51.8%) receiving DES and 27 (48.2%) receiving BMS or 
angioplasty alone. Clopidogrel discontinuation did not increase cardiovascular events significantly in the BMS group (p =0.586). In the DES group, 
5 adverse events (2 deaths, 2 MI, 1 PCI) occurred in the clopidogrel discontinuation group compared to none in the clopidogrel continuation group 
(29.4% vs. 0%, p= .0389). All adverse events in the DES group occurred between 4 and 12 months post-PCI (mean 283 days) and in subjects 
receiving elective and non-elective procedures.
Conclusions: The perioperative cessation of clopidogrel in post-DES patients is associated with major adverse cardiovascular outcomes. All 
physicians caring for post-PCI patients perioperatively should be aware of this risk. Further study is needed to clarify the optimal management 
strategy of antiplatelet agents in post-PCI patients receiving noncardiac surgery.
